Similar Posts
Is this oil stock too good a bargain to ignore: Parex Resources (TSE:PXT)?
Parex Resources Inc. (XTSE: PXT) is a crude oil exploration, development, and production company. The business utilizes technologies developed in Western Canada’s Sedimentary Basin to South American basins with significant oil-in-place potential. The majority of the company’s properties are in Colombia, where it pays the government a royalty or tax for its activities. Parex relies on a team of geologists, geophysicists, and technology like 3D seismic surveys to aid exploration activities. Oil output is marketed to a restricted group of South and North American players.
Fox Corporation: Evaluating News Dominance, Sports Rights, and Streaming Expansion
Fox Corporation is a media company focused primarily on live news, sports broadcasting, and television entertainment, generating revenue through advertising, affiliate fees, and content licensing.
The U.S.-Canada Trade War Is Getting Bigger: Which Industries Could Win and Lose?
A New Phase in North American Trade Trade tensions between the United States and Canada have escalated sharply. After negotiations broke down, President Donald Trump threatened to raise tariffs on Canadian cars, trucks, automotive parts and steel to 50% from January 1, 2027. Canada has also announced retaliatory measures on selected U.S. goods beginning September…
Is it the right time to invest in this uranium miner: Cameco Corp. (TSX:CCO)?
Cameco Corp. (TSX: CCO), is one of the largest global providers of the uranium fuel needed to energize a clean-air world. The company operates through two segments: Uranium and Fuel Services. The Uranium segment is involved in the exploration for, mining, and milling, as well as purchase and sale of uranium concentrate. The Fuel Services segment engages in the refining, conversion, and fabrication of uranium.
The corporation holds interests in tier-one mining and milling operations that have the licensed capacity to produce more than 30 million pounds of uranium concentrates annually, backed by more than 464 million pounds of proven and probable mineral reserves.
Is Protagonist Therapeutics Inc. (NASDAQ: PTGX) a good buy from biotechnology Industry?
Protagonist Therapeutics, Inc.(XNAS:PGTX) is a biopharmaceutical company that discovers and develops peptide based therapeutic drugs to address hematology and blood disorders, as well as inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with polycythemia vera and hereditary hemochromatosis, as well as for the treatment of other blood disorders; PN-943, an oral, alpha-4-beta-7 antagonist peptide, which is currently in Phase II clinical trials for the treatment of inflammatory bowel disease (IBD); and PN-235, an interleukin-23 receptor antagonist for the treatment of both IBD and non-IBD indications. A license and collaboration agreement has been signed between the company and Janssen Biotech Inc.
SandRidge Energy, Inc.: Strong Balance Sheet, Strategic Optionality
nergy, Inc. engages in the acquisition, development, and production of oil, natural gas, and natural gas liquids in the United States Mid-Continent region.